Pneumonia adquirida na comunidade em adultos

Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-67.Texto completo  Resumo

Jones BE, Ramirez JA, Oren E, et al. Diagnosis and management of community-acquired pneumonia. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2025 Jul 18.Texto completo  Resumo

Miller JM, Binnicker MJ, Campbell S, et al. Guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2024 update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). Clin Infect Dis. 2024 Mar 5:ciae104.Texto completo  Resumo

1. Simonetti AF, Viasus D, Garcia-Vidal C, et al. Management of community-acquired pneumonia in older adults. Ther Adv Infect Dis. 2014 Feb;2(1):3-16.Texto completo  Resumo

2. Masiá M, Gutiérrez F, Padilla S, et al. Clinical characterisation of pneumonia caused by atypical pathogens combining classic and novel predictors. Clin Microbiol Infect. 2007 Feb;13(2):153-61.Texto completo  Resumo

3. Vaughn VM, Dickson RP, Horowitz JK, et al. Community-acquired pneumonia: a review. JAMA. 2024 Oct 15;332(15):1282-95. Resumo

4. Centers for Disease Control and Prevention. National center for health statistics: pneumonia. Jul 2025 [internet publication].Texto completo

5. Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among US adults. N Engl J Med. 2015 Jul 30;373(5):415-27.Texto completo  Resumo

6. Institute for Health Metrics and Evaluation. Lower respiratory infections - level 3 cause. 2019 [internet publication].Texto completo

7. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17:396(10258):1204-22.Texto completo  Resumo

8. National Institute for Health and Care Excellence. Pneumonia in adults: diagnosis and management. Oct 2023 [internet publication].Texto completo

9. Rice LB. Antimicrobial resistance in gram-positive bacteria. Am J Med. 2006 Jun;119(suppl 1):S11-9. Resumo

10. Cillóniz C, Ewig S, Polverino E, et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax. 2011 Apr;66(4):340-6.Texto completo  Resumo

11. Cillóniz C, Ewig S, Polverino E, et al. Community-acquired pneumonia in outpatients: aetiology and outcomes. Eur Respir J. 2012 Oct;40(4):931-8.Texto completo  Resumo

12. Cilloniz C, Torres A, Polverino E, et al. Community-acquired lung respiratory infections in HIV-infected patients: microbial aetiology and outcome. Eur Respir J. 2014 Jun;43(6):1698-708.Texto completo  Resumo

13. Almirall J, Boixeda R, Bolíbar I, et al. Differences in the etiology of community-acquired pneumonia according to site of care: a population-based study. Respir Med. 2007 Oct;101(10):2168-75.Texto completo  Resumo

14. GBD 2019 Antimicrobial Resistance Collaborators. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022 Dec 17;400(10369):2221-48.Texto completo  Resumo

15. Isturiz R, Grant L, Gray S, et al. Expanded analysis of 20 pneumococcal serotypes associated with radiographically confirmed community-acquired pneumonia in hospitalized US adults. Clin Infect Dis. 2021 Oct 5;73(7):1216-22.Texto completo  Resumo

16. Isturiz RE, Ramirez J, Self WH, et al. Pneumococcal epidemiology among us adults hospitalized for community-acquired pneumonia. Vaccine. 2019 May 31;37(25):3352-61.Texto completo  Resumo

17. Lansbury L, McKeever TM, Lawrence H, et al. Pneumococcal pneumonia trends in adults hospitalised with community-acquired pneumonia over 10 years (2013-2023) and the role of serotype 3. Thorax. 2025 Jan 17;80(2):86-96. Resumo

18. Marchello C, Dale AP, Thai TN, et al. Prevalence of atypical pathogens in patients with cough and community-acquired pneumonia: a meta-analysis. Ann Fam Med. 2016 Nov;14(6):552-66.Texto completo  Resumo

19. Arnold FW, Summersgill JT, Ramirez JA. Role of atypical pathogens in the etiology of community-acquired pneumonia. Semin Respir Crit Care Med. 2016 Dec;37(6):819-28. Resumo

20. Garin N, Marti C, Skali Lami A, et al. Atypical pathogens in adult community-acquired pneumonia and implications for empiric antibiotic treatment: a narrative review. Microorganisms. 2022 Nov 24;10(12):2326.Texto completo  Resumo

21. Tagini F, Opota O, Greub G. Chlamydia pneumoniae upsurge at tertiary hospital, Lausanne, Switzerland. Emerg Infect Dis. 2024 Apr;30(4):810-2.Texto completo  Resumo

22. Graham FF, Finn N, White P, et al. Global perspective of legionella infection in community-acquired pneumonia: a systematic review and meta-analysis of observational studies. Int J Environ Res Public Health. 2022 Feb 8;19(3):1907.Texto completo  Resumo

23. Hogerwerf L, DE Gier B, Baan B, et al. Chlamydia psittaci (psittacosis) as a cause of community-acquired pneumonia: a systematic review and meta-analysis. Epidemiol Infect. 2017 Nov;145(15):3096-105. Resumo

24. Spoorenberg SM, Bos WJ, van Hannen EJ, et al. Chlamydia psittaci: a relevant cause of community-acquired pneumonia in two Dutch hospitals. Neth J Med. 2016 Feb;74(2):75-81. Resumo

25. Cillóniz C, Dominedò C, Nicolini A, et al. PES pathogens in severe community-acquired pneumonia. Microorganisms. 2019 Feb 12;7(2):E49.Texto completo  Resumo

26. Prina E, Ranzani OT, Polverino E, et al. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc. 2015 Feb;12(2):153-60. Resumo

27. Jokinen C, Heiskanen L, Juvonen H, et al. Microbial etiology of community-acquired pneumonia in the adult population of 4 municipalities in eastern Finland. Clin Infect Dis. 2001 Apr 15;32(8):1141-54.Texto completo  Resumo

28. Jennings LC, Anderson TP, Beynon KA, et al. Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax. 2008 Jan;63(1):42-8.Texto completo  Resumo

29. Burk M, El-Kersh K, Saad M, et al. Viral infection in community-acquired pneumonia: a systematic review and meta-analysis. Eur Respir Rev. 2016 Jun;25(140):178-88.Texto completo  Resumo

30. Malinis M, Abbo L, Vazquez JA, et al. Community-acquired pneumonia: a US perspective on the guideline gap. J Antimicrob Chemother. 2024 May 2;79(5):959-61.Texto completo  Resumo

31. Scobie HM, Johnson AG, Suthar AB, et al. Monitoring incidence of COVID-19 cases, hospitalizations, and deaths, by vaccination status - 13 U.S. Jurisdictions, April 4-July 17, 2021. MMWR Morb Mortal Wkly Rep. 2021 Sep 17;70(37):1284-90.Texto completo  Resumo

32. McLaughlin JM, Khan F, Begier E, et al. Rates of medically attended RSV among US adults: a systematic review and meta-analysis. Open Forum Infect Dis. 2022 Jul;9(7):ofac300.Texto completo  Resumo

33. Kim T, Huh JW, Hong SB, et al. Epidemiology and characteristics of respiratory syncytial virus pneumonia in critically ill adults. Open Forum Infect Dis. 2023 Apr;10(4):ofad131.Texto completo  Resumo

34. Cillóniz C, Dominedò C, Magdaleno D, et al. Pure viral sepsis secondary to community-acquired pneumonia in adults: risk and prognostic factors. J Infect Dis. 2019 Aug 30;220(7):1166-71. Resumo

35. Wunderink RG, Waterer G. Advances in the causes and management of community acquired pneumonia in adults. BMJ. 2017 Jul 10;358:j2471. Resumo

36. Johansson N, Kalin M, Tiveljung-Lindell A, et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis. 2010 Jan 15;50(2):202-9.Texto completo  Resumo

37. Alcón A, Fàbregas N, Torres A. Pathophysiology of pneumonia. Clin Chest Med. 2005 Mar;26(1):39-46. Resumo

38. Torres A, Peetermans WE, Viegi G, et al. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013 Nov;68(11):1057-65.Texto completo  Resumo

39. Rumbak MJ. The pathogenesis of ventilator-associated pneumonia. Semin Respir Crit Care Med. 2002 Oct;23(5):427-34. Resumo

40. Dickson RP, Erb-Downward JR, Huffnagle GB. Towards an ecology of the lung: new conceptual models of pulmonary microbiology and pneumonia pathogenesis. Lancet Respir Med. 2014 Mar;2(3):238-46.Texto completo  Resumo

41. Wu BG, Segal LN. The lung microbiome and its role in pneumonia. Clin Chest Med. 2018 Dec;39(4):677-89. Resumo

42. Man WH, de Steenhuijsen Piters WA, Bogaert D. The microbiota of the respiratory tract: gatekeeper to respiratory health. Nat Rev Microbiol. 2017 May;15(5):259-70. Resumo

43. Cillóniz C, Polverino E, Ewig S, et al. Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. Chest. 2013 Sep;144(3):999-1007. Resumo

44. Polverino E, Dambrava P, Cillóniz C, et al. Nursing home-acquired pneumonia: a 10 year single-centre experience. Thorax. 2010 Apr;65(4):354-9.Texto completo  Resumo

45. Sund-Levander M, Ortqvist A, Grodzinsky E, et al. Morbidity, mortality and clinical presentation of nursing home-acquired pneumonia in a Swedish population. Scand J Infect Dis. 2003;35(5):306-10. Resumo

46. Molinos L, Clemente MG, Miranda B, et al. Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease. J Infect. 2009 Jun;58(6):417-24. Resumo

47. Kohlhammer Y, Schwartz M, Raspe H, et al. Risk factors for community acquired pneumonia (CAP): a systematic review [in German]. Dtsch Med Wochenschr. 2005 Feb 25;130(8):381-6. Resumo

48. Garcia-Vidal C, Ardanuy C, Tubau F, et al. Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes. Thorax. 2010 Jan;65(1):77-81. Resumo

49. Gordin FM, Roediger MP, Girard PM, et al. Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption. Am J Respir Crit Care Med. 2008 Sep 15;178(6):630-6. Resumo

50. Bello S, Menéndez R, Torres A, et al. Tobacco smoking increases the risk for death from pneumococcal pneumonia. Chest. 2014 Oct;146(4):1029-37. Resumo

51. Baskaran V, Murray RL, Hunter A, et al. Effect of tobacco smoking on the risk of developing community acquired pneumonia: a systematic review and meta-analysis. PLoS One. 2019 Jul 18;14(7):e0220204.Texto completo  Resumo

52. Almirall J, Serra-Prat M, Bolíbar I, et al. Passive smoking at home is a risk factor for community-acquired pneumonia in older adults: a population-based case-control study. BMJ Open. 2014 Jun 13;4(6):e005133.Texto completo  Resumo

53. Simou E, Britton J, Leonardi-Bee J. Alcohol and the risk of pneumonia: a systematic review and meta-analysis. BMJ Open. 2018 Aug 22;8(8):e022344.Texto completo  Resumo

54. Samokhvalov AV, Irving HM, Rehm J. Alcohol consumption as a risk factor for pneumonia: a systematic review and meta-analysis. Epidemiol Infect. 2010 Dec;138(12):1789-95. Resumo

55. Cao Y, Liu C, Lin J, et al. Oral care measures for preventing nursing home-acquired pneumonia. Cochrane Database Syst Rev. 2022 Nov 16;11(11):CD012416.Texto completo  Resumo

56. Abramowitz J, Thakkar P, Isa A, et al. Adverse event reporting for proton pump inhibitor therapy: an overview of systematic reviews. Otolaryngol Head Neck Surg. 2016 Oct;155(4):547-54. Resumo

57. Lambert AA, Lam JO, Paik JJ, et al. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015 Jun 4;10(6):e0128004.Texto completo  Resumo

58. Eom CS, Jeon CY, Lim JW, et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011 Feb 22;183(3):310-9.Texto completo  Resumo

59. Liapikou A, Cilloniz C, Torres A, et al. Drugs that increase the risk of community-acquired pneumonia: a narrative review. Expert Opin Drug Saf. 2018 Oct;17(10):991-1003. Resumo

60. Almirall J, Bolíbar I, Serra-Prat M, et al. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J. 2008 Jun;31(6):1274-84.Texto completo  Resumo

61. Schnoor M, Klante T, Beckmann M, et al. Risk factors for community-acquired pneumonia in German adults: the impact of children in the household. Epidemiol Infect. 2007 Nov;135(8):1389-97.Texto completo  Resumo

62. Teepe J, Grigoryan L, Verheij TJ. Determinants of community-acquired pneumonia in children and young adults in primary care. Eur Respir J. 2010 May;35(5):1113-7.Texto completo  Resumo

63. Cillóniz C, García-Vidal C, Moreno A, et al. Community-acquired bacterial pneumonia in adult HIV-infected patients. Expert Rev Anti Infect Ther. 2018 Jul;16(7):579-88. Resumo

64. Kornum JB, Thomsen RW, Riis A, et al. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care. 2008 Aug;31(8):1541-5.Texto completo  Resumo

65. Yende S, van der Poll T, Lee M, et al. The influence of pre-existing diabetes mellitus on the host immune response and outcome of pneumonia: analysis of two multicentre cohort studies. Thorax. 2010 Oct;65(10):870-7.Texto completo  Resumo

66. Kang CI, Song JH, Kim SH, et al. Risk factors and pathogenic significance of bacteremic pneumonia in adult patients with community-acquired pneumococcal pneumonia. J Infect. 2013 Jan;66(1):34-40. Resumo

67. From S, Targowski T. The risk factors of death in community-acquired pneumonia [in Polish]. Pol Merkur Lekarski. 2002 Jun;12(72):455-7. Resumo

68. Chidiac C, Che D, Pires-Cronenberger S, et al. Factors associated with hospital mortality in community-acquired legionellosis in France. Eur Respir J. 2012 Apr;39(4):963-70.Texto completo  Resumo

69. Fernández J, Navasa M, Gómez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002 Jan;35(1):140-8.Texto completo  Resumo

70. Cillóniz C, Ewig S, Polverino E, et al. Pulmonary complications of pneumococcal community-acquired pneumonia: incidence, predictors, and outcomes. Clin Microbiol Infect. 2012 Nov;18(11):1134-42.Texto completo  Resumo

71. Edelman EJ, Gordon KS, Crothers K, et al. Association of prescribed opioids with increased risk of community-acquired pneumonia among patients with and without HIV. JAMA Intern Med. 2019 Mar 1;179(3):297-304. Resumo

72. Kobayashi M, Pilishvili T, Farrar JL, et al. Pneumococcal vaccine for adults aged ≥19 years: recommendations of the Advisory Committee on Immunization Practices, United States, 2023. MMWR Recomm Rep. 2023 Sep 8;72(3):1-39.Texto completo  Resumo

73. Centers for Disease Control and Prevention. Respiratory syncytial virus infection (RSV): ​RSV vaccines. Jul 2025 [internet publication].Texto completo

74. Centers for Disease Control and Prevention. ​Advisory Committee on Immunization Practices (ACIP) recommendations. Aug 2025 [internet publication].Texto completo

75. National Institute for Health and Care Research. Pneumonia vaccine is effective in people with inflammatory diseases. Dec 2024 [internet publication].Texto completo

76. Bennett JC, Deloria Knoll M, Kagucia EW, et al. Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis. Lancet Infect Dis. 2025 Apr;25(4):457-70.Texto completo  Resumo

77. Tan L, Trevas D, Falsey AR. Adult vaccine coadministration is safe, effective, and acceptable: results of a survey of the literature. Influenza Other Respir Viruses. 2025 Mar;19(3):e70090.Texto completo  Resumo

78. Padhani ZA, Moazzam Z, Ashraf A, et al. Vitamin C supplementation for prevention and treatment of pneumonia. Cochrane Database Syst Rev. 2021 Nov 18;11:CD013134.Texto completo  Resumo

79. Public Health England. Insufficient evidence for vitamin D preventing or treating ARTIs. Jul 2020 [internet publication].Texto completo

80. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-67.Texto completo  Resumo

81. Marti C, Garin N, Grosgurin O, et al. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care. 2012 Jul 27;16(4):R141.Texto completo  Resumo

82. Cheng GS, Crothers K, Aliberti S, et al. Immunocompromised host pneumonia: definitions and diagnostic criteria: an official American Thoracic Society workshop report. Ann Am Thorac Soc. 2023 Mar;20(3):341-53.Texto completo  Resumo

83. Torres A, Barberán J, Falguera M, et al. Multidisciplinary guidelines for the management of community-acquired pneumonia [in Spanish]. Med Clin (Barc). 2013 Mar 2;140(5):223.e1-223.e19. Resumo

84. Barbagelata E, Cillóniz C, Dominedò C, et al. Gender differences in community-acquired pneumonia. Minerva Med. 2020 Apr;111(2):153-65. Resumo

85. American College of Radiology. ACR appropriateness criteria®: acute respiratory illness in immunocompetent patients.​ 2024 [internet publication].Texto completo

86. Niederman MS. Imaging for the management of community-acquired pneumonia: what to do if the chest radiograph is clear. Chest. 2018 Mar;153(3):583-5. Resumo

87. Qaseem A, Etxeandia-Ikobaltzeta I, Mustafa RA, et al. Appropriate use of point-of-careultrasonography in patients with acute dyspnea in emergency department or inpatientsettings: a clinical guideline from the American College of Physicians. Ann Intern Med. 2021Jul;174(7):985-93.Texto completo  Resumo

88. Reissig A, Gramegna A, Aliberti S. The role of lung ultrasound in the diagnosis and follow-up of community-acquired pneumonia. Eur J Intern Med. 2012 Jul;23(5):391-7. Resumo

89. Llamas-Álvarez AM, Tenza-Lozano EM, Latour-Pérez J. Accuracy of lung ultrasonography in the diagnosis of pneumonia in adults: systematic review and meta-analysis. Chest. 2017 Feb;151(2):374-82. Resumo

90. Orso D, Guglielmo N, Copetti R. Lung ultrasound in diagnosing pneumonia in the emergency department: a systematic review and meta-analysis. Eur J Emerg Med. 2018 Oct;25(5):312-21. Resumo

91. Gartlehner G, Wagner G, Affengruber L, et al. Point-of-care ultrasonography in patients with acute dyspnea: an evidence report for a clinical practice guideline by the American College of Physicians. Ann Intern Med. 2021 Jul;174(7):967-76.Texto completo  Resumo

92. Ye X, Xiao H, Chen B, et al. Accuracy of lung ultrasonography versus chest radiography for the diagnosis of adult community-acquired pneumonia: review of the literature and meta-analysis. PLoS One. 2015;10(6):e0130066.Texto completo  Resumo

93. Jones BE, Ramirez JA, Oren E, et al. Diagnosis and management of community-acquired pneumonia. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2025 Jul 18.Texto completo  Resumo

94. Claessens YE, Debray MP, Tubach F, et al. Early chest computed tomography scan to assist diagnosis and guide treatment decision for suspected community-acquired pneumonia. Am J Respir Crit Care Med. 2015 Oct 15;192(8):974-82. Resumo

95. Miller JM, Binnicker MJ, Campbell S, et al. Guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2024 update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). Clin Infect Dis. 2024 Mar 5:ciae104.Texto completo  Resumo

96. Del Rio-Pertuz G, Gutiérrez JF, Triana AJ, et al. Usefulness of sputum gram stain for etiologic diagnosis in community-acquired pneumonia: a systematic review and meta-analysis. BMC Infect Dis. 2019 May 10;19(1):403.Texto completo  Resumo

97. Losier A, Dela Cruz CS. New testing guidelines for community-acquired pneumonia. Curr Opin Infect Dis. 2022 Apr 1;35(2):128-32. Resumo

98. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997 Jan 23;336(4):243-50.Texto completo  Resumo

99. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003 May;58(5):377-82.Texto completo  Resumo

100. Montassier E, Javaudin F, Moustafa F, et al. Guideline-based clinical assessment versus procalcitonin-guided antibiotic use in pneumonia: a pragmatic randomized trial. Ann Emerg Med. 2019 Oct;74(4):580-91. Resumo

101. Womack J, Kropa J. Community-acquired pneumonia in adults: rapid evidence review. Am Fam Physician. 2022 Jun 1;105(6):625-30.Texto completo  Resumo

102. Menéndez R, Cavalcanti M, Reyes S, et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax. 2008 May;63(5):447-52.Texto completo  Resumo

103. Woodhead M. New guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2011 Dec;38(6):1250-1.Texto completo  Resumo

104. Menéndez R, Sahuquillo-Arce JM, Reyes S, et al. Cytokine activation patterns and biomarkers are influenced by microorganisms in community-acquired pneumonia. Chest. 2012 Jun;141(6):1537-45. Resumo

105. Ugajin M, Yamaki K, Hirasawa N, et al. Predictive values of semi-quantitative procalcitonin test and common biomarkers for the clinical outcomes of community-acquired pneumonia. Respir Care. 2014 Apr;59(4):564-73.Texto completo  Resumo

106. Sundaralingam A, Banka R, Rahman NM. Management of pleural infection. Pulm Ther. 2021 Jun;7(1):59-74.Texto completo  Resumo

107. Sirvent JM, Vidaur L, Gonzalez S, et al. Microscopic examination of intracellular organisms in protected bronchoalveolar mini-lavage fluid for the diagnosis of ventilator-associated pneumonia. Chest. 2003 Feb;123(2):518-23. Resumo

108. Darie AM, Khanna N, Jahn K, et al. Fast multiplex bacterial PCR of bronchoalveolar lavage for antibiotic stewardship in hospitalised patients with pneumonia at risk of gram-negative bacterial infection (Flagship II): a multicentre, randomised controlled trial. Lancet Respir Med. 2022 Sep;10(9):877-87. Resumo

109. Murdoch DR. How recent advances in molecular tests could impact the diagnosis of pneumonia. Expert Rev Mol Diagn. 2016;16(5):533-40. Resumo

110. Elnifro EM, Ashshi AM, Cooper RJ, et al. Multiplex PCR: optimization and application in diagnostic virology. Clin Microbiol Rev. 2000 Oct;13(4):559-70.Texto completo  Resumo

111. Trujillo-Gómez J, Tsokani S, Arango-Ferreira C, et al. Biofire FilmArray Meningitis/Encephalitis panel for the aetiological diagnosis of central nervous system infections: a systematic review and diagnostic test accuracy meta-analysis. EClinicalMedicine. 2022 Feb;44:101275.Texto completo  Resumo

112. Rajbhandari P, Goodrich N, Nabower AM, et al. Current state and practice variation in the use of Meningitis/Encephalitis (ME) FilmArray panel in children. BMC Infect Dis. 2022 Oct 31;22(1):811.Texto completo  Resumo

113. Evans SE, Jennerich AL, Azar MM, et al. Nucleic acid-based testing for noninfluenza viral pathogens in adults with suspected community-acquired pneumonia. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2021 May 1;203(9):1070-87.Texto completo  Resumo

114. Simundic AM, Bölenius K, Cadamuro J, et al. Joint EFLM-COLABIOCLI recommendation for venous blood sampling. Clin Chem Lab Med 2018;56(12):2015-38. Resumo

115. Darden DB, Hawkins RB, Larson SD, et al. The clinical presentation and immunology of viral pneumonia and implications for management of coronavirus disease 2019. Crit Care Explor. 2020 Apr 29;2(4):e0109.Texto completo  Resumo

116. Struyf T, Deeks JJ, Dinnes J, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19. Cochrane Database Syst Rev. 2022 May 20;(5):CD013665.Texto completo  Resumo

117. Sadiq Z, Rana S, Mahfoud Z, et al. Systematic review and meta-analysis of chest radiograph (CXR) findings in COVID-19. Clin Imaging. 2021 Dec;80:229-38.Texto completo  Resumo

118. González-Moraleja J, Sesma P, González C, et al. What is the cost of inappropriate admission of pneumonia patients? [in Spanish]. Arch Bronconeumol. 1999 Jul-Aug;35(7):312-6. Resumo

119. Smith MD, Fee C, et al. Clinical policy: critical issues in the management of adult patients presenting to the emergency department with community-acquired pneumonia. Ann Emerg Med. 2021 Jan;77(1):e1-57. Resumo

120. España PP, Capelastegui A, Gorordo I, et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med. 2006 Dec 1;174(11):1249-56.Texto completo  Resumo

121. Charles PG, Wolfe R, Whitby M, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008 Aug 1;47(3):375-84.Texto completo  Resumo

122. Restrepo MI, Mortensen EM, Rello J, et al. Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest. 2010 Mar;137(3):552-7.Texto completo  Resumo

123. Brown SM, Jones JP, Aronsky D, et al. Relationships among initial hospital triage, disease progression and mortality in community-acquired pneumonia. Respirology. 2012 Nov;17(8):1207-13.Texto completo  Resumo

124. Phua J, Ngerng WJ, Lim TK. The impact of a delay in intensive care unit admission for community-acquired pneumonia. Eur Respir J. 2010 Oct;36(4):826-33.Texto completo  Resumo

125. Aliberti S, Ramirez J, Cosentini R, et al. Low CURB-65 is of limited value in deciding discharge of patients with community-acquired pneumonia. Respir Med. 2011 Nov;105(11):1732-8.Texto completo  Resumo

126. Sharp AL, Jones JP, Wu I, et al. CURB-65 performance among admitted and discharged emergency department patients with community-acquired pneumonia. Acad Emerg Med. 2016 Apr;23(4):400-5. Resumo

127. Niederman M. In the clinic: community-acquired pneumonia. Ann Intern Med. 2009 Oct 6;151(7):ITC4-2-ITC4. Resumo

128. Halm EA, Teirstein AS. Clinical practice: management of community-acquired pneumonia. N Engl J Med. 2002 Dec 19;347(25):2039-45. Resumo

129. Furuya EY, Lowy FD. Antimicrobial-resistant bacteria in the community setting. Nat Rev Microbiol. 2006 Jan;4(1):36-45. Resumo

130. Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: does antimicrobial resistance matter? Semin Respir Crit Care Med. 2009 Apr;30(2):210-38. Resumo

131. Fenoll A, Granizo JJ, Aguilar L, et al. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol. 2009 Apr;47(4):1012-20.Texto completo  Resumo

132. Dagan R, Klugman KP. Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis. 2008 Dec;8(12):785-95. Resumo

133. Aspa J, Rajas O, de Castro FR. Pneumococcal antimicrobial resistance: therapeutic strategy and management in community-acquired pneumonia. Expert Opin Pharmacother. 2008 Feb;9(2):229-41. Resumo

134. O'Driscoll BR, Howard LS, Earis J, et al. British Thoracic Society Guideline for oxygen use in adults in healthcare and emergency settings. BMJ Open Respir Res. 2017 May 15;4(1):e000170.Texto completo  Resumo

135. Naucler P, Strålin K. Routine atypical antibiotic coverage is not necessary in hospitalised patients with non-severe community-acquired pneumonia. Int J Antimicrob Agents. 2016 Aug;48(2):224-5. Resumo

136. Postma DF, van Werkhoven CH, Oosterheert JJ. Community-acquired pneumonia requiring hospitalization: rational decision making and interpretation of guidelines. Curr Opin Pulm Med. 2017 May;23(3):204-10. Resumo

137. File TM Jr, Marrie TJ. Does empiric therapy for atypical pathogens improve outcomes for patients with CAP? Infect Dis Clin North Am. 2013 Mar;27(1):99-114. Resumo

138. File TM Jr, Eckburg PB, Talbot GH, et al. Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point. Int J Antimicrob Agents. 2017 Aug;50(2):247-51. Resumo

139. Eljaaly K, Alshehri S, Aljabri A, et al. Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis. BMC Infect Dis. 2017 Jun 2;17(1):385.Texto completo  Resumo

140. Rusu A, Munteanu AC, Arbănași EM, et al. Overview of side-effects of antibacterial fluoroquinolones: new drugs versus old drugs, a step forward in the safety profile? Pharmaceutics. 2023 Mar 1;15(3):804.Texto completo  Resumo

141. Garnacho-Montero J, Barrero-García I, Gómez-Prieto MG, et al. Severe community-acquired pneumonia: current management and future therapeutic alternatives. Expert Rev Anti Infect Ther. 2018 Sep;16(9):667-77. Resumo

142. Furukawa Y, Luo Y, Funada S, et al. Optimal duration of antibiotic treatment for community-acquired pneumonia in adults: a systematic review and duration-effect meta-analysis. BMJ Open. 2023 Mar 22;13(3):e061023.Texto completo  Resumo

143. Kuijpers SME, Buis DTP, Ziesemer KA, et al. The evidence base for the optimal antibiotic treatment duration of upper and lower respiratory tract infections: an umbrella review. Lancet Infect Dis. 2025 Jan;25(1):94-113. Resumo

144. Uranga A, España PP, Bilbao A, et al. Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial. JAMA Intern Med. 2016 Sep 1;176(9):1257-65. Resumo

145. Lee RA, Centor RM, Humphrey LL, et al. Appropriate use of short-course antibiotics in common infections: best practice advice from the American College of Physicians. Ann Intern Med. 2021 Jun;174(6):822-7.Texto completo  Resumo

146. Vaughn VM, Flanders SA, Snyder A, et al. Excess antibiotic treatment duration and adverse events in patients hospitalized with pneumonia: a multihospital cohort study. Ann Intern Med. 2019 Aug 6;171(3):153-63. Resumo

147. Lan SH, Lai CC, Chang SP, et al. Five-day antibiotic treatment for community-acquired bacterial pneumonia: a systematic review and meta-analysis of randomized controlled trials. J Glob Antimicrob Resist. 2020 Dec;23:94-9.Texto completo  Resumo

148. Dinh A, Ropers J, Duran C, et al. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial. Lancet. 2021 Mar 27;397(10280):1195-203. Resumo

149. Chaudhuri D, Nei AM, Rochwerg B, et al. 2024 Focused update: guidelines on use of corticosteroids in sepsis, acute respiratory distress syndrome, and community-acquired pneumonia. Crit Care Med. 2024 May 1;52(5):e219-33.Texto completo  Resumo

150. Smit JM, Van Der Zee PA, Stoof SCM, et al. Predicting benefit from adjuvant therapy with corticosteroids in community-acquired pneumonia: a data-driven analysis of randomised trials. Lancet Respir Med. 2025 Mar;13(3):221-33. Resumo

151. Saleem N, Kulkarni A, Snow TAC, et al. Effect of corticosteroids on mortality and clinical cure in community-acquired pneumonia: a systematic review, meta-analysis, and meta-regression of randomized control trials. Chest. 2023 Mar;163(3):484-97.Texto completo  Resumo

152. Dequin PF, Meziani F, Quenot JP, et al. Hydrocortisone in severe community-acquired pneumonia. N Engl J Med. 2023 May 25;388(21):1931-41.Texto completo  Resumo

153. Pitre T, Abdali D, Chaudhuri D, et al. Corticosteroids in community-acquired bacterial pneumonia: a systematic review, pairwise and dose-response meta-analysis. J Gen Intern Med. 2023 Aug;38(11):2593-606.Texto completo  Resumo

154. Briel M, Spoorenberg SMC, Snijders D, et al. Corticosteroids in patients hospitalized with community-acquired pneumonia: systematic review and individual patient data meta-analysis. Clin Infect Dis. 2018 Jan 18;66(3):346-54. Resumo

155. Stern A, Skalsky K, Avni T, et al. Corticosteroids for pneumonia. Cochrane Database Syst Rev. 2017 Dec 13;12:CD007720.Texto completo  Resumo

156. Aliberti S, Blasi F. Clinical stability versus clinical failure in patients with community-acquired pneumonia. Semin Respir Crit Care Med. 2012 Jun;33(3):284-91. Resumo

157. Menendez R, Torres A. Treatment failure in community-acquired pneumonia. Chest. 2007 Oct;132(4):1348-55. Resumo

158. Póvoa P, Coelho L, Cidade JP, et al. Biomarkers in pulmonary infections: a clinical approach. Ann Intensive Care. 2024 Jul 17;14(1):113.Texto completo  Resumo

159. Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2017 Oct 12;(10):CD007498.Texto completo  Resumo

160. Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018 Jan;18(1):95-107. Resumo

161. Lam SW, Bauer SR, Fowler R, et al. Systematic review and meta-analysis of procalcitonin-guidance versus usual care for antimicrobial management in critically ill patients: focus on subgroups based on antibiotic initiation, cessation, or mixed strategies. Crit Care Med. 2018 May;46(5):684-90. Resumo

162. Huang DT, Yealy DM, Filbin MR, et al. Procalcitonin-guided use of antibiotics for lower respiratory tract infection. N Engl J Med. 2018 Jul 19;379(3):236-49.Texto completo  Resumo

163. Smedemark SA, Aabenhus R, Llor C, et al. Biomarkers as point-of-care tests to guide prescription of antibiotics in people with acute respiratory infections in primary care. Cochrane Database Syst Rev. 2022 Oct 17;10(10):CD010130.Texto completo  Resumo

164. Schuetz P, Bolliger R, Merker M, et al. Procalcitonin-guided antibiotic therapy algorithms for different types of acute respiratory infections based on previous trials. Expert Rev Anti Infect Ther. 2018 Jul;16(7):555-64. Resumo

165. Centers for Disease Control and Prevention. ​Valley fever: testing algorithm for coccidioidomycosis. May 2024 [internet publication].Texto completo

166. Centers for Disease Control and Prevention. Testing algorithm for histoplasmosis​. May 2024 [internet publication].Texto completo

167. Centers for Disease Control and Prevention. Fungal diseases: fungal community-acquired pneumonias​. May 2024 [internet publication].Texto completo

168. Lloyd M, Karahalios A, Janus E, et al. Effectiveness of a bundled intervention including adjunctive corticosteroids on outcomes of hospitalized patients with community-acquired pneumonia: a stepped-wedge randomized clinical trial. JAMA Intern Med. 2019 Aug 1;179(8):1052-60. Resumo

169. Soar J, Böttiger BW, Carli P, et al. European Resuscitation Council Guidelines 2021: adult advanced life support. Resuscitation. 2021 Apr;161:115-51.Texto completo  Resumo

170. Colquhoun MC, Handley AJ, Evans TR, eds. ABC of resuscitation. 5th ed. Wiley-Blackwell; 2004.

171. Chrimes N, Higgs A, Hagberg CA, et al. Preventing unrecognised oesophageal intubation: a consensus guideline from the Project for Universal Management of Airways and international airway societies. Anaesthesia. 2022 Aug 17 [Epub ahead of print].Texto completo  Resumo

172. Kusminsky RE. Complications of central venous catheterization. J Am Coll Surg. 2007 Apr;204(4):681-96.Texto completo  Resumo

173. McGee DC, Gould MK. Preventing complications of central venous catheterization. N Engl J Med. 2003 Mar 20;348(12):1123-33.Texto completo  Resumo

174. Smith RN, Nolan JP. Central venous catheters. BMJ. 2013 Nov 11;347:f6570.Texto completo  Resumo

175. Reich DL. Monitoring in anesthesia and perioperative care. Cambridge: Cambridge University Press; 2011.

176. Abbott Northwestern Hospital Internal Medicine Residency. Internal jugular central venous line. 2022 [internet publication].Texto completo

177. Bishop L, Dougherty L, Bodenham A, et al. Guidelines on the insertion and management of central venous access devices in adults. Int J Lab Hematol. 2007 Aug;29(4):261-78.Texto completo  Resumo

178. Practice guidelines for central venous access 2020: an updated report by the American Society of Anesthesiologists Task Force on Central Venous Access. Anesthesiology. 2020 Jan;132(1):8-43.Texto completo  Resumo

179. Fletcher SJ, Bodenham AR. Safe placement of central venous catheters: where should the tip of the catheter lie? Br J Anaesth. 2000 Aug;85(2):188-91.Texto completo

180. Gibson F, Bodenham A. Misplaced central venous catheters: applied anatomy and practical management. Br J Anaesth. 2013 Mar;110(3):333-46.Texto completo

181. Schuster M, Nave H, Piepenbrock S, et al. The carina as a landmark in central venous catheter placement. Br J Anaesth. 2000 Aug;85(2):192-4.Texto completo

182. Webster J, Osborne S, Rickard CM, et al. Clinically-indicated replacement versus routine replacement of peripheral venous catheters. Cochrane Database Syst Rev. 2019 Jan 23;1(1):CD007798.Texto completo  Resumo

183. Grudzinska FS, Dosanjh DP, Parekh D, et al. Statin therapy in patients with community-acquired pneumonia. Clin Med (Lond). 2017 Oct;17(5):403-7.Texto completo  Resumo

184. Wang ST, Sun XF. Role of statins in treatment and prevention of community-acquired pneumonia: a meta-analysis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2018 Feb 28;40(1):30-40. Resumo

185. Dillon C, Guarascio AJ, Covvey JR. Lefamulin: a promising new pleuromutilin antibiotic in the pipeline. Expert Rev Anti Infect Ther. 2019 Jan;17(1):5-15. Resumo

186. Paukner S, Gelone SP, Arends SJR, et al. Antibacterial activity of lefamulin against pathogens most commonly causing community-acquired bacterial pneumonia: SENTRY Antimicrobial Surveillance Program (2015-2016). Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02161-18.Texto completo  Resumo

187. Veve MP, Wagner JL. Lefamulin: review of a promising novel pleuromutilin antibiotic. Pharmacotherapy. 2018 Sep;38(9):935-46. Resumo

188. File TM Jr, Goldberg L, Das A, et al. Efficacy and safety of IV-to-oral lefamulin, a pleuromutilin antibiotic, for treatment of community-acquired bacterial pneumonia: the phase 3 LEAP 1 trial. Clin Infect Dis. 2019 Nov 13;69(11):1856-67.Texto completo  Resumo

189. Alexander E, Goldberg L, Das AF, et al. Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia: the LEAP 2 randomized clinical trial. JAMA. 2019 Nov 5;322(17):1661-71. Resumo

190. Chahine EB, Sucher AJ. Lefamulin: the first systemic pleuromutilin antibiotic. Ann Pharmacother. 2020 Dec;54(12):1203-14. Resumo

191. ClinicalTrials.gov. Study to compare delafloxacin to moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (DEFINE-CABP). Feb 2020 [internet publication].Texto completo

192. Stets R, Popescu M, Gonong JR, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019 Feb 7;380(6):517-27.Texto completo  Resumo

193. Hsu WH, Hsu CK, Lai CC. Ceftobiprole medocaril for the treatment of pneumonia. Expert Rev Anti Infect Ther. 2023 Jun;21(6):551-63.Texto completo  Resumo

194. Chang SP, Lee HZ, Lai CC, et al. The efficacy and safety of nemonoxacin compared with levofloxacin in the treatment of community-acquired pneumonia: a systemic review and meta-analysis of randomized controlled trials. Infect Drug Resist. 2019 Feb 14;12:433-8.Texto completo  Resumo

195. Oldach D, Clark K, Schranz J, et al. Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia. Antimicrob Agents Chemother. 2013 Jun;57(6):2526-34.Texto completo  Resumo

196. File TM Jr, Rewerska B, Vucinic-Mihailovic V, et al. SOLITAIRE-IV: a randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia. Clin Infect Dis. 2016 Oct 15;63(8):1007-16.Texto completo  Resumo

197. Carella F, Aliberti S, Stainer A, et al. Long-term outcomes in severe community-acquired pneumonia. Semin Respir Crit Care Med. 2024 Apr;45(2):266-73. Resumo

198. Ramirez JA. Cognitive decline in pneumonia: a neglected consequence. [in spa]. Arch Bronconeumol. 2025 Apr;61(4):189-90.

199. Luna HI, Pankey G. The utility of blood culture in patients with community-acquired pneumonia. Ochsner J. 2001 Apr;3(2):85-93.Texto completo  Resumo

200. Torres A, Cillóniz C, Ferrer M, et al. Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis. Eur Respir J. 2015 May;45(5):1353-63. Resumo

201. Sligl WI, Marrie TJ. Severe community-acquired pneumonia. Crit Care Clin. 2013 Jul;29(3):563-601. Resumo

202. Melzer M, Welch C. 30-day mortality in UK patients with bacteraemic community-acquired pneumonia. Infection. 2013 Oct;41(5):1005-11. Resumo

203. Jasti H, Mortensen EM, Obrosky DS, et al. Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia. Clin Infect Dis. 2008 Feb 15;46(4):550-6.Texto completo  Resumo

204. Capelastegui A, España Yandiola PP, Quintana JM, et al. Predictors of short-term rehospitalization following discharge of patients hospitalized with community-acquired pneumonia. Chest. 2009 Oct;136(4):1079-85. Resumo

205. Desai A, Aliberti S, Amati F, et al. Cardiovascular complications in community-acquired pneumonia. Microorganisms. 2022 Nov 2;10(11):2177.Texto completo  Resumo

206. Viasus D, Del Rio-Pertuz G, Simonetti AF, et al. Biomarkers for predicting short-term mortality in community-acquired pneumonia: a systematic review and meta-analysis. J Infect. 2016 Mar;72(3):273-82. Resumo

207. Jiang J, Yang J, Jin Y, et al. Role of qSOFA in predicting mortality of pneumonia: a systematic review and meta-analysis. Medicine (Baltimore). 2018 Oct;97(40):e12634.Texto completo  Resumo

208. Cillóniz C, Dominedò C, Ielpo A, et al. Risk and prognostic factors in very old patients with sepsis secondary to community-acquired pneumonia. J Clin Med. 2019 Jul 2;8(7):E961.Texto completo  Resumo

209. Cilloniz C, Ferrer M, Liapikou A, et al. Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia. Eur Respir J. 2018 Mar 29;51(3):1702215.Texto completo  Resumo

210. Wee LE, Lim JT, Ho RWL, et al. Cardiac events in adults hospitalized for respiratory syncytial virus vs COVID-19 or influenza. JAMA Netw Open. 2025 May 1;8(5):e2511764.Texto completo  Resumo

211. Feldman C. Cardiac complications in community-acquired pneumonia and COVID-19. Afr J Thorac Crit Care Med. 2020 May 14;26(2):10.Texto completo  Resumo

212. Corrales-Medina VF, Suh KN, Rose G, et al. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med. 2011 Jun;8(6):e1001048.Texto completo  Resumo

213. Becker T, Moldoveanu A, Cukierman T, et al. Clinical outcomes associated with the use of subcutaneous insulin-by-glucose sliding scales to manage hyperglycemia in hospitalized patients with pneumonia. Diabetes Res Clin Pract. 2007 Dec;78(3):392-7. Resumo

214. Ramirez J, Aliberti S, Mirsaeidi M, et al. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis. 2008 Jul 15;47(2):182-7.Texto completo  Resumo

215. Corrales-Medina VF, Serpa J, Rueda AM, et al. Acute bacterial pneumonia is associated with the occurrence of acute coronary syndromes. Medicine (Baltimore). 2009 May;88(3):154-9. Resumo

216. Light RW, Girard WM, Jenkinson SG, et al. Parapneumonic effusions. Am J Med. 1980 Oct;69(4):507-12. Resumo

217. Taryle DA, Potts DE, Sahn SA. The incidence and clinical correlates of parapneumonic effusions in pneumococcal pneumonia. Chest. 1978 Aug;74(2):170-3. Resumo

218. Menéndez R, Torres A, Zalacaín R, et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax. 2004 Nov;59(11):960-5.Texto completo  Resumo

219. Tsai YF, Ku YH. Necrotizing pneumonia: a rare complication of pneumonia requiring special consideration. Curr Opin Pulm Med. 2012 May;18(3):246-52. Resumo

220. Ross I, Bick S, Ayieko P, et al. Effectiveness of handwashing with soap for preventing acute respiratory infections in low-income and middle-income countries: a systematic review and meta-analysis. Lancet. 2023 May 20;401(10389):1681-90.Texto completo  Resumo